AG
DYN icon

Artal Group’s Dyne Therapeutics DYN Stock Holding History

Artal Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,516,960
Closed -$53.5M – 30
2024
Q2 		$53.5M Sell
1,516,960
-1,000
-0.1% -$29.1K 1.36% 8
2024
Q1 		$43.1M Buy
1,517,960
+300,000
+25% +$6.78M 1.1% 12
2023
Q4 		$16.2M Buy
1,217,960
+402,875
+49% +$3.94M 0.54% 26
2023
Q3 		$7.3M Hold
815,085
– – 0.31% 51
2023
Q2 		$9.17M Buy
815,085
+282,476
+53% +$3.33M 0.28% 53
2023
Q1 		$6.14M Buy
532,609
+7,609
+1% +$98.8K 0.36% 57
2022
Q4 		$6.08M Hold
525,000
– – 0.34% 55
2022
Q3 		$6.67M Hold
525,000
– – 0.28% 54
2022
Q2 		$3.61M Hold
525,000
– – 0.19% 74
2022
Q1 		$5.06M Hold
525,000
– – 0.21% 76
2021
Q4 		$6.24M Hold
525,000
– – 0.17% 90
2021
Q3 		$8.53M Hold
525,000
– – 0.19% 88
2021
Q2 		$11M Hold
525,000
– – 0.22% 84
2021
Q1 		$8.15M Buy
525,000
+225,000
+75% +$4.35M 0.14% 107
2020
Q4 		$6.3M Sell
300,000
-70,000
-19% -$1.38M 0.14% 102
2020
Q3 		$7.47M Buy
+370,000
New +$8.12M 0.18% 84

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Artal Group's DYN Position: Q3 2024 in Review

Artal Group sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 1,516,960 shares — an estimated $53.5M sold.

Artal Group first reported a position in DYN in Q3 2020 and held it in 16 quarters. The position peaked at $53.5M in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Artal Group reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,516,960 Dyne Therapeutics shares in Q3 2024, an estimated $53.5M.
  • Artal Group first reported a position in Dyne Therapeutics in Q3 2020 and held it in 16 quarters.
  • Artal Group's Dyne Therapeutics position peaked at $53.5M in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.